

# Antonio Avallone

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/568818/antonio-avallone-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

171  
papers

3,787  
citations

29  
h-index

54  
g-index

198  
ext. papers

4,677  
ext. citations

4.5  
avg, IF

4.92  
L-index

#	Paper	IF	Citations
171	Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.. <i>Clinical Colorectal Cancer</i> , <b>2022</b> ,	3.8	3
170	Contrast MR-Based Radiomics and Machine Learning Analysis to Assess Clinical Outcomes following Liver Resection in Colorectal Liver Metastases: A Preliminary Study.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	6
169	HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2022</b> , 41, 83	12.8	1
168	Magnetic Resonance Features of Liver Mucinous Colorectal Metastases: What the Radiologist Should Know.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	4
167	Radiomics and Machine Learning Analysis Based on Magnetic Resonance Imaging in the Assessment of Colorectal Liver Metastases Growth Pattern. <i>Diagnostics</i> , <b>2022</b> , 12, 1115	3.8	6
166	Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy. <i>Biomedicines</i> , <b>2022</b> , 10, 1035	4.8	0
165	Electrochemotherapy of Primary Colon Rectum Cancer and Local Recurrence: Case Report and Prospective Analysis. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 2745	5.1	0
164	Skin Toxicity as Predictor of Survival in Refractory Patients with Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
163	From Seismic Monitoring to Tsunami Warning in the Mediterranean Sea. <i>Seismological Research Letters</i> , <b>2021</b> , 92, 1796-1816	3	8
162	Clinical Phase I/II Study: Local Disease Control and Survival in Locally Advanced Pancreatic Cancer Treated with Electrochemotherapy. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4
161	Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis. <i>Journal of Translational Medicine</i> , <b>2021</b> , 19, 132	8.5	7
160	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , <b>2021</b> , 146, 74-83	7.5	8
159	Validation of the standardized index of shape tool to analyze DCE-MRI data in the assessment of neo-adjuvant therapy in locally advanced rectal cancer. <i>Radiologia Medica</i> , <b>2021</b> , 126, 1044-1054	6.5	16
158	Organ Sparing for Locally Advanced Rectal Cancer after Neoadjuvant Treatment Followed by Electrochemotherapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
157	Radiomics in hepatic metastasis by colorectal cancer. <i>Infectious Agents and Cancer</i> , <b>2021</b> , 16, 39	3.5	21
156	Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2118475	10.4	3
155	CliniciansPAAttitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. <i>Clinical Colorectal Cancer</i> , <b>2021</b> ,	3.8	4

154	Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 1758835921989223	5.4	0
153	Radiomics-Derived Data by Contrast Enhanced Magnetic Resonance in RAS Mutations Detection in Colorectal Liver Metastases. <i>Cancers</i> , <b>2021</b> , 13,	6.6	28
152	Perspectives in the Treatment of or Mutated Metastatic Colorectal Cancer Patients. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 602596	5.3	1
151	The safety and efficacy of Glubran 2 as biliostatic agent in liver resection. <i>Infectious Agents and Cancer</i> , <b>2021</b> , 16, 19	3.5	5
150	Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma. <i>Infectious Agents and Cancer</i> , <b>2021</b> , 16, 53	3.5	7
149	Watch and Wait Approach for Rectal Cancer Following Neoadjuvant Treatment: The Experience of a High Volume Cancer Center. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	3
148	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1529-1535	13.4	13
147	A Multicenter Randomized Controlled Prospective Study to Assess Efficacy of Laparoscopic Electrochemotherapy in the Treatment of Locally Advanced Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
146	TRIBE2 results and toxicity. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, e299	21.7	
145	Magnetic resonance imaging in the assessment of pancreatic cancer with quantitative parameter extraction by means of dynamic contrast-enhanced magnetic resonance imaging, diffusion kurtosis imaging and intravoxel incoherent motion diffusion-weighted imaging. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835921989223	4.7	22
144	Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 270-276	3.8	
143	Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy. <i>Journal of Translational Medicine</i> , <b>2020</b> , 18, 34	8.5	7
142	Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma <b>2020</b> ,		3
141	Abbreviated MRI protocol for colorectal liver metastases: How the radiologist could work in pre surgical setting. <i>PLoS ONE</i> , <b>2020</b> , 15, e0241431	3.7	15
140	Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1430-1442	3.3	15
139	Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part I: Classification, diagnosis and staging. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1282-1293	3.3	21
138	Radiological assessment of secondary biliary tree lesions: an update. <i>Journal of International Medical Research</i> , <b>2020</b> , 48, 300060519850398	1.4	4
137	Study of Ras Mutations Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	6

136	Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with -mutated metastatic colorectal cancer: the REVOLUTION study protocol. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920929589	5.4	4
135	Diffusion-Weighted MRI and Diffusion Kurtosis Imaging to Detect RAS Mutation in Colorectal Liver Metastasis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	19
134	Intravoxel Incoherent Motion Model of Diffusion Weighted Imaging and Diffusion Kurtosis Imaging in Differentiating of Local Colorectal Cancer Recurrence from Scar/Fibrosis Tissue by Multivariate Logistic Regression Analysis. <i>Applied Sciences (Switzerland)</i> , <b>2020</b> , 10, 8609	2.6	0
133	Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 766	5.3	12
132	Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. <i>BMC Cancer</i> , <b>2019</b> , 19, 899	4.8	8
131	Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 1089-1096	3.5	2
130	Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer Aged at Least 75 Years: A Post-Hoc Subgroup Analysis of Three Phase II Trials. <i>Cancers</i> , <b>2019</b> , 11,	6.6	2
129	F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 1560-1568	8.9	7
128	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the BRAF BeCoolP study. <i>European Journal of Cancer</i> , <b>2019</b> , 118, 121-130	7.5	29
127	Diagnostic performance of gadoxetic acid-enhanced liver MRI versus multidetector CT in the assessment of colorectal liver metastases compared to hepatic resection. <i>BMC Gastroenterology</i> , <b>2019</b> , 19, 129	3	32
126	Heterogeneous Behavior of the Campotosto Normal Fault (Central Italy) Imaged by InSAR GPS and Strong-Motion Data: Insights from the 18 January 2017 Events. <i>Remote Sensing</i> , <b>2019</b> , 11, 1482	5	14
125	Joint Inversion of Coseismic and Early Postseismic Slip to Optimize the Information Content in Geodetic Data: Application to the 2009 Mw6.3 L'Aquila Earthquake, Central Italy. <i>Journal of Geophysical Research: Solid Earth</i> , <b>2019</b> , 124, 10522-10543	3.6	14
124	Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS731-TPS731	2.2	6
123	The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge. <i>Radiology and Oncology</i> , <b>2019</b> , 53, 373-387	3.8	22
122	Unravelling the contribution of early postseismic deformation using sub-daily GNSS positioning. <i>Scientific Reports</i> , <b>2019</b> , 9, 1775	4.9	23
121	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. <i>ESMO Open</i> , <b>2019</b> , 4, e000519	6	3
120	Qualitative assessment of EOB-GD-DTPA and Gd-BT-DO3A MR contrast studies in HCC patients and colorectal liver metastases. <i>Infectious Agents and Cancer</i> , <b>2019</b> , 14, 40	3.5	15
119	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , <b>2019</b> , 10, 591-597	3.6	4

118	Diffusion and perfusion MR parameters to assess preoperative short-course radiotherapy response in locally advanced rectal cancer: a comparative explorative study among Standardized Index of Shape by DCE-MRI, intravoxel incoherent motion- and diffusion kurtosis imaging-derived parameters. <i>Abdominal Radiology</i> , <b>2019</b> , 44, 3683-3700	3	19
117	Morphological and functional features prognostic factor of magnetic resonance imaging in locally advanced rectal cancer. <i>Acta Radiologica</i> , <b>2019</b> , 60, 815-825	2	2
116	First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 441	5.6	6
115	DCE-MRI time-intensity curve visual inspection to assess pathological response after neoadjuvant therapy in locally advanced rectal cancer. <i>Japanese Journal of Radiology</i> , <b>2018</b> , 36, 611-621	2.9	6
114	Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication?. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 62	5.3	1
113	Obesity and Cancer: Biological Links and Treatment Implications. <i>Current Cancer Drug Targets</i> , <b>2018</b> , 18, 231-238	2.8	13
112	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , <b>2018</b> , 95, 344-352	3.6	9
111	A radiologist's point of view in the presurgical and intraoperative setting of colorectal liver metastases. <i>Future Oncology</i> , <b>2018</b> , 14, 2189-2206	3.6	18
110	HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS3135-TPS3135	2.2	6
109	Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. <i>PLoS ONE</i> , <b>2018</b> , 13, e0191593	3.7	6
108	Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors. <i>Oncotarget</i> , <b>2018</b> , 9, 35251-35265	3.3	3
107	Update survival analysis from a multicenter, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3562-3562	2.2	
106	Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples. <i>Frontiers in Public Health</i> , <b>2018</b> , 6, 291	6	1
105	The DISTINCTIVE study: A biologically enriched phase II study of second-line folfiri/aflibercept in prospectively stratified, anti-EGFR resistant, metastatic colorectal cancer patients with RAS Validated wild type status - Trial in progress. <i>Annals of Oncology</i> , <b>2018</b> , 29, v82	10.3	3
104	Assessing response to neo-adjuvant therapy in locally advanced rectal cancer using Intra-voxel Incoherent Motion modelling by DWI data and Standardized Index of Shape from DCE-MRI. <i>Therapeutic Advances in Medical Oncology</i> , <b>2018</b> , 10, 1758835918809875	5.4	12
103	Posterior HOX genes and HOTAIR expression in the proximal and distal colon cancer pathogenesis. <i>Journal of Translational Medicine</i> , <b>2018</b> , 16, 350	8.5	29
102	Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials. <i>Acta Oncologica</i> , <b>2017</b> , 56, 377-383	3.2	35
101	T1 colon cancer in the era of screening: risk factors and treatment. <i>Techniques in Coloproctology</i> , <b>2017</b> , 21, 139-147	2.9	5

100	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , <b>2017</b> , 20, 825-833	7.6	24
99	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , <b>2017</b> , 13, 2265-2275	3.6	8
98	Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2017</b> , 36, 177	12.8	23
97	FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land. <i>Cancer Letters</i> , <b>2017</b> , 408, 71-72	9.9	1
96	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , <b>2017</b> , 22, 1463-1469	5.7	17
95	Near-source high-rate GPS, strong motion and InSAR observations to image the 2015 Lefkada (Greece) Earthquake rupture history. <i>Scientific Reports</i> , <b>2017</b> , 7, 10358	4.9	17
94	Uncommon neoplasms of the biliary tract: radiological findings. <i>British Journal of Radiology</i> , <b>2017</b> , 90, 20160561	3.4	8
93	Aseismic transient during the 2010-2014 seismic swarm: evidence for longer recurrence of M 6.5 earthquakes in the Pollino gap (Southern Italy)?. <i>Scientific Reports</i> , <b>2017</b> , 7, 576	4.9	19
92	MR imaging perfusion and diffusion analysis to assess preoperative Short Course Radiotherapy response in locally advanced rectal cancer: Standardized Index of Shape by DCE-MRI and intravoxel incoherent motion-derived parameters by DW-MRI. <i>Medical Oncology</i> , <b>2017</b> , 34, 198	3.7	14
91	Peribiliary liver metastases MR findings. <i>Medical Oncology</i> , <b>2017</b> , 34, 124	3.7	9
90	Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update. <i>Infectious Agents and Cancer</i> , <b>2017</b> , 12, 23	3.5	24
89	Natural killer cells activity in a metastatic colorectal cancer patient with complete and long lasting response to therapy. <i>World Journal of Clinical Cases</i> , <b>2017</b> , 5, 390-396	1.6	7
88	Sequential PET/CT with [18F]-FDG Predicts Pathological Tumor Response to Preoperative Short Course Radiotherapy with Delayed Surgery in Patients with Locally Advanced Rectal Cancer Using Logistic Regression Analysis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0169462	3.7	9
87	Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases. <i>PLoS ONE</i> , <b>2017</b> , 12, e0179951	3.7	28
86	Standardized Index of Shape (DCE-MRI) and Standardized Uptake Value (PET/CT): Two quantitative approaches to discriminate chemo-radiotherapy locally advanced rectal cancer responders under a functional profile. <i>Oncotarget</i> , <b>2017</b> , 8, 8143-8153	3.3	28
85	Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: Lights and shadows. <i>Oncotarget</i> , <b>2017</b> , 8, 51224-51237	3.3	28
84	Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples. <i>Anticancer Research</i> , <b>2017</b> , 37, 1975-1978	2.3	6
83	A Combined Velocity Field of the Mediterranean Region. <i>Annals of Geophysics</i> , <b>2017</b> , 60,	1.1	84

82	Coseismic deformation, field observations and seismic fault of the 17 November 2015 M = 6.5, Lefkada Island, Greece earthquake. <i>Tectonophysics</i> , <b>2016</b> , 687, 210-222	3.1	36
81	A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme). <i>BMC Cancer</i> , <b>2016</b> , 16, 69	4.8	14
80	Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy. <i>Oncology</i> , <b>2016</b> , 90, 36-42	3.6	45
79	Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 366-74	12.5	41
78	A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer. <i>Journal of Geriatric Oncology</i> , <b>2016</b> , 7, 134-41	3.6	17
77	GPS observations of coseismic deformation following the 2016, August 24, Mw 6 Amatrice earthquake (central Italy): data, analysis and preliminary fault model. <i>Annals of Geophysics</i> , <b>2016</b> , 59,	1.1	13
76	Coseismic displacement waveforms for the 2016 August 24 Mw 6.0 Amatrice earthquake (central Italy) carried out from High-Rate GPS data. <i>Annals of Geophysics</i> , <b>2016</b> , 59,	1.1	14
75	Prognostic factors in 868 advanced gastric cancer patients exposed to second-line therapy.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e15553-e15553	2.2	
74	Intravoxel incoherent motion (IVIM) in diffusion-weighted imaging (DWI) for Hepatocellular carcinoma: correlation with histologic grade. <i>Oncotarget</i> , <b>2016</b> , 7, 79357-79364	3.3	56
73	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. <i>Oncotarget</i> , <b>2016</b> , 7, 69060-69074	3.3	21
72	Evaluation of Tumor Response after Short-Course Radiotherapy and Delayed Surgery for Rectal Cancer. <i>PLoS ONE</i> , <b>2016</b> , 11, e0160732	3.7	18
71	Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1564	2.2	5
70	Surgery has a key role for quality assurance of colorectal cancer screening programs: impact of the third level multidisciplinary team on lymph nodal staging. <i>International Journal of Colorectal Disease</i> , <b>2016</b> , 31, 587-92	3	2
69	Standardized Index of Shape (SIS): a quantitative DCE-MRI parameter to discriminate responders by non-responders after neoadjuvant therapy in LARC. <i>European Radiology</i> , <b>2015</b> , 25, 1935-45	8	35
68	The target sign in colorectal liver metastases: an atypical Gd-EOB-DTPA "uptake" on the hepatobiliary phase of MR imaging. <i>Abdominal Imaging</i> , <b>2015</b> , 40, 2364-71		30
67	Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. <i>Oncotarget</i> , <b>2015</b> , 6, 28716-30	3.3	9
66	Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging. <i>PLoS ONE</i> , <b>2015</b> , 10, e0142876	3.7	65
65	MRI for Assessing Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer Using DCE-MR and DW-MR Data Sets: A Preliminary Report. <i>BioMed Research International</i> , <b>2015</b> , 2015, 514740 <sup>3</sup>		27

64	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , <b>2015</b> , 21, 795-801	50.5	557
63	A perspective on the current treatment strategies for locally advanced rectal cancer. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2015</b> , 65, 192-6	5.6	3
62	Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial. <i>Oncotarget</i> , <b>2015</b> , 6, 30394-407	3.3	31
61	Raise and decline of KRAS mutant clones in colorectal cancers (CRCs) treated with multiple rounds of anti-EGFR antibodies.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 11073-11073	2.2	
60	New perspective for an old antidiabetic drug: metformin as anticancer agent. <i>Cancer Treatment and Research</i> , <b>2014</b> , 159, 355-76	3.5	99
59	Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. <i>Expert Opinion on Drug Safety</i> , <b>2014</b> , 13, 113-29	4.1	25
58	Strong motion displacement waveforms using 10-Hz precise point positioning GPS: an assessment based on free oscillation experiments. <i>Earthquake Engineering and Structural Dynamics</i> , <b>2014</b> , 43, 1853-1866	4.6	31
57	Waveguide effects in very high rate GPS record of the 6 April 2009, Mw 6.1 L'Aquila, central Italy earthquake. <i>Journal of Geophysical Research: Solid Earth</i> , <b>2014</b> , 119, 490-501	3.6	19
56	An update on the management of metastatic colorectal cancer in the elderly. <i>Colorectal Cancer</i> , <b>2014</b> , 3, 451-463	0.8	2
55	Role of Magnetic Resonance Imaging in Locally Advanced Rectal Cancer <b>2014</b> ,		2
54	Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial). <i>BMC Cancer</i> , <b>2014</b> , 14, 875	4.8	27
53	A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 379-90	7.5	27
52	XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 257-64	3.5	17
51	Multidisciplinary approach to rectal cancer: are we ready for selective treatment strategies?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2013</b> , 13, 852-60	2.2	14
50	Gastrointestinal non colorectal cancer. Do elderly patients need a specific management?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2013</b> , 13, 1364-70	2.2	
49	Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 1978-83	4.3	7
48	Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 1848-57	8.8	47
47	High-rate (1 Hz to 20 Hz) GPS coseismic dynamic displacements carried out during the Emilia 2012 seismic sequence. <i>Annals of Geophysics</i> , <b>2012</b> , 55,	1.1	3



46	GPS observations of coseismic deformation following the May 20 and 29, 2012, Emilia seismic events (northern Italy): data, analysis and preliminary models. <i>Annals of Geophysics</i> , <b>2012</b> , 55,	1.1	13
45	Accuracy of endoscopic ultrasound in staging and restaging patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2011</b> , 35, 666-70	2.4	26
44	Dynamic Contrast Enhanced Magnetic Resonance Imaging in Rectal Cancer <b>2011</b> ,		3
43	Molecular analysis of Fanconi anemia and mismatch repair genes in patients with colorectal carcinoma. <i>Oncology Reports</i> , <b>2011</b> , 25, 899-904	3.5	0
42	Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 79, 670-6	4	25
41	Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 1680-91	8.7	38
40	Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial. <i>Lung Cancer</i> , <b>2010</b> , 68, 94-8	5.9	6
39	Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet. <i>Acta Oncologica</i> , <b>2010</b> , 49, 50-6	3.2	7
38	Optimizing the management of metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2010</b> , 75, 15-26	7	3
37	The RING network: improvement of a GPS velocity field in the central Mediterranean. <i>Annals of Geophysics</i> , <b>2010</b> , 53,	1.1	9
36	Role of oxaliplatin in the treatment of colorectal cancer. <i>Therapeutics and Clinical Risk Management</i> , <b>2009</b> , 5, 229-38	2.9	40
35	Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 782-91	4.6	58
34	Preoperative radiotherapy "short course" in rectal cancer in elder patient: low impact on tumor regression. <i>BMC Geriatrics</i> , <b>2009</b> , 9,	4.1	78
33	Locally Advanced Rectal Cancer: Combined Chemotherapy During Preoperative Radiation Therapy <b>2009</b> , 411-436		
32	Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence. <i>Drugs</i> , <b>2008</b> , 68, 949-61	12.1	14
31	Chemo-radiotherapy in locally advanced rectal cancer: What is the optimal strategy?. <i>European Journal of Cancer, Supplement</i> , <b>2008</b> , 6, 70-73	1.6	3
30	Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2008</b> , 65, 164-71	7	6
29	Intra-patient alternated dose escalation of paclitaxel and gemcitabine versus paclitaxel followed by fixed dose rate infusion of gemcitabine in fit elderly non-small cell lung cancer patients. A Southern Italy Cooperative Oncology Group randomised phase II trial. <i>Lung Cancer</i> , <b>2007</b> , 56, 263-71	5.9	5

28	Post-treatment fistulas in patients with rectal cancer: MRI with rectal superparamagnetic contrast agent. <i>Abdominal Imaging</i> , <b>2007</b> , 32, 328-31		13
27	Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 781-91	2.4	11
26	A Multitemporal Method for Correction of Tropospheric Effects in Differential SAR Interferometry: Application to the Gulf of Corinth Earthquake. <i>IEEE Transactions on Geoscience and Remote Sensing</i> , <b>2007</b> , 45, 1605-1615	8.1	31
25	Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 617-25	12.9	77
24	Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study. <i>British Journal of Cancer</i> , <b>2006</b> , 94, 1809-15	8.7	32
23	<sup>18</sup> F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. <i>Journal of Nuclear Medicine</i> , <b>2006</b> , 47, 1241-8	8.9	151
22	The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2005</b> , 11, 209-16	2.2	29
21	Analysis of eleven years of deformation measured by GPS in the Corinth Rift Laboratory area. <i>Comptes Rendus - Geoscience</i> , <b>2004</b> , 336, 301-311	1.4	123
20	Microsatellite instability and mutation analysis among southern Italian patients with colorectal carcinoma: detection of different alterations accounting for MLH1 and MSH2 inactivation in familial cases. <i>Annals of Oncology</i> , <b>2003</b> , 14, 1530-6	10.3	12
19	Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (Presta), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. <i>Journal of Cellular Physiology</i> , <b>2003</b> , 195, 139-50	7	117
18	Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. <i>British Journal of Cancer</i> , <b>2002</b> , 86, 1871-5	8.7	24
17	Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. <i>Annals of Oncology</i> , <b>2002</b> , 13, 866-73	10.3	23
16	Cisplatin, raltitrexed, levofolonic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study. <i>Oncology</i> , <b>2002</b> , 63, 232-8	3.6	14
15	Prevalence and prognostic role of microsatellite instability in patients with rectal carcinoma. <i>Annals of Oncology</i> , <b>2002</b> , 13, 1447-53	10.3	35
14	Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies. <i>Annals of Oncology</i> , <b>2002</b> , 13, 1874-81	10.3	19
13	Phase I study of mitoxantrone, raltitrexed, levofolonic acid and 5-fluorouracil in advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2001</b> , 47, 113-6	3.5	2
12	Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG). <i>Annals of Oncology</i> , <b>2001</b> , 12, 199-202	10.3	26
11	Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group. <i>Oncology</i> , <b>2001</b> , 60, 127-33	3.6	7

10	Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy. <i>Anti-Cancer Drugs</i> , <b>2001</b> , 12, 489-97	2.4	6
9	Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group. <i>Annals of Oncology</i> , <b>2000</b> , 11, 461-8	10.3	10
8	Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. <i>Annals of Oncology</i> , <b>2000</b> , 11, 1323-33	10.3	24
7	Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer. <i>Annals of Oncology</i> , <b>2000</b> , 11, 339-42	10.3	34
6	Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG). <i>Annals of Oncology</i> , <b>2000</b> , 11, 575-80	10.3	8
5	Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group. <i>Annals of Oncology</i> , <b>1999</b> , 10, 915-21	10.3	13
4	A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck <b>1999</b> , 85, 952-959		6
3	Beta- and gamma-catenin expression in thyroid carcinomas. <i>Journal of Pathology</i> , <b>1998</b> , 185, 267-72	9.4	46
2	Alpha 1 B, but not alpha 1A, adrenoreceptor activates calcium influx through the stimulation of a tyrosine kinase/phosphotyrosine phosphatase pathway, following noradrenaline-induced emptying of IP3 sensitive calcium stores, in PC Cl3 rat thyroid cell line. <i>Biochemical and Biophysical Research Communications</i> , <b>1995</b> , 209, 630-8	3.4	22
1	Effect of acetyl-L-carnitine treatment on brain adenylate cyclase activity in young and aged rats. <i>European Neuropsychopharmacology</i> , <b>1993</b> , 3, 95-101	1.2	2